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Abstract
Background: Although reperfusion injury has been shown to be responsible for cardiomyocytes death after an
acute myocardial infarction, there is currently no drug on the market that reduces this type of injury. TRO40303
is a new cardioprotective compound that was shown to inhibit the opening of the mitochondrial permeability
transition pore and reduce infarct size after ischemia-reperfusion in a rat model of cardiac ischemia-reperfusion
injury.
Methods: In the rat model, the therapeutic window and the dose effect relationship were investigated in order
to select the proper dose and design for clinical investigations. To evaluate post-ischemic functional recovery,
TRO40303 was tested in a model of isolated rat heart. Additionally, TRO40303 was investigated in a Phase I
randomized, double-blind, placebo controlled study to assess the safety, tolerability and pharmacokinetics of
single intravenous ascending doses of the compound (0.5 to 13 mg/kg) in 72 healthy male, post-menopausal and
hysterectomized female subjects at flow rates from 0.04 to 35 mL/min (EudraCT number: 2010-021453-39). This work
was supported in part by the French Agence Nationale de la Recherche.
Results: In the vivo model, TRO40303 reduced infarct size by 40% at 1 mg/kg and by 50% at 3 and 10 mg/kg
given by intravenous bolus and was only active when administered before reperfusion. Additionally, TRO40303
provided functional recovery and reduced oxidative stress in the isolated rat heart model.
These results, together with pharmacokinetic based allometry to human and non-clinical toxicology data, were used
to design the Phase I trial. All the tested doses and flow rates were well tolerated clinically. There were no serious
adverse events reported. No relevant changes in vital signs, electrocardiogram parameters, laboratory tests or
physical examinations were observed at any time in any dose group. Pharmacokinetics was linear up to 6 mg/kg
and slightly ~1.5-fold, hyper-proportional from 6 to 13 mg/kg.
Conclusions: These data demonstrated that TRO40303 can be safely administered by the intravenous route in
humans at doses expected to be pharmacologically active. These results allowed evaluating the expected active
dose in human at 6 mg/kg, used in a Phase II proof-of-concept study currently ongoing.
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Background
According to the World Health Organisation, cardiovas-
cular diseases remain one of the leading causes of death
in the world. A large number of people suffering from
cardiac ischemia (e.g. myocardial infarction) die or suffer
from cardiac dysfunction leading very often to a new
cardiovascular event in the following years. These dismal
statistics make it indisputable that these diseases are to
be considered as having highly unmet medical needs.
During an acute myocardial infarction, ischemia and
subsequent reperfusion each contribute to the loss of vi-
able myocardium leading to alterations in left ventricular
structure remodelling, reduced heart function and heart
failure. Early myocardial reperfusion with the use of
thrombolytic therapy or primary percutaneous coronary
intervention (PCI) is the most effective strategy for redu-
cing myocardial infarct size and improving the clinical
outcome. However, because myocardial reperfusion para-
doxically induces cardiomyocyte death [1,2], there has
been an increased recognition of the need for treatments
that reduce reperfusion injury [3-8]. Evidence indicates
that opening of the mitochondrial permeability transition
pore (mPTP) is largely involved in reperfusion injury [9]
and that inhibitors of mPTP such as Cyclosporine A
(INN: ciclosporin) can reduce reperfusion injury [10].
TRO40303 ( 3,5-seco-4-nor-cholestan-5-one oxime-3-ol)
is a newly discovered compound that inhibits mPTP open-
ing via an innovative mode of action [11]. TRO40303 is
targeted to the cardiac mitochondria likely through bind-
ing to the cholesterol site of the outer mitochondrial
membrane translocator protein (TSPO). TRO40303 has
been shown to reduce infarct size in a model of myocar-
dial infarction in rats while at the same time inhibiting
AIF (Apoptosis Inducing Factor) release from mitochon-
dria to the cytosol in the ischemic area, potentially via the
reduction of oxidative stress [11]. However TRO40303
does not increase the calcium retention capacity of iso-
lated mitochondria as does Cyclosporine A, probably
because TRO40303 inhibits the mPTP by another mech-
anism than Cyclosporine A, which targets the mitochon-
drial matrix protein Cyclophilin D.
Translating a potential therapeutic from the bench to the
bedside for an emergency indication such as myocardial in-
farction presents several important challenges. These in-
clude 1) establishing a pharmacokinetic-pharmacodynamic
(PK/PD) relationship, 2) identifying the therapeutic window
with respect to the clinical setting, 3) developing a formula-
tion able to rapidly and safely deliver an effective dose and
4) confirming safety and PK parameters in healthy volun-
teers. This has not always been adequately investigated in
the case of some previously developed cardioprotective
compounds [12-14]. These issues are especially challenging
with a poorly soluble or highly hydrophobic compound
such as TRO40303 and for an acute care emergency
indication such as an acute myocardial infarction where 1)
time is critical so injection time is short making it import-
ant to find an excipient that maximizes solubility to
minimize volume and injection time and 2) patients are un-
stable so less able to tolerate side effects known to be asso-
ciated with emulsion formulations used to deliver poorly
soluble compounds.
To address these challenges, we had to develop spe-
cific formulations for the preclinical and the clinical
investigations. Previous studies showed that 2.5 mg/kg
of TRO40303 [11], formulated in hydroxypropyl-beta-
cyclodextrine (HPBCD) reduced infarct size by 38% in a
myocardial infarction model in rats [11]. Because of the
limited solubility in HPBCD, the maximum dose that
could be tested using this vehicle was limited by the vol-
ume that could be administered (5 mL/kg). To increase
exposure and explore a full dose-response relationship,
TRO40303 was formulated in Intralipid® 30 (IL30), an
oil-based parenteral nutritional supplement that pro-
vides improved TRO40303 solubility to concentrations
up to ~6 mg/mL. Using this IL30 formulation, we evalu-
ated the cardioprotective effects of TRO40303 by evalu-
ating infarct size in a model of myocardial infarction in
rats in terms of dose-effect relationship and therapeutic
window in greater detail to derive a PK/PD relationship
and to identify the optimal time of administration. Fur-
ther studies also explored the functional recovery and
gathered further evidence for TRO40303s mechanism
of action in an ex vivo model of cardiac ischemia-
reperfusion injury. Recovery of left ventricular function,
as assessed in the ex vivo model, is of extreme import-
ance as together with infarct size, as assessed in the
in vivo model, left ventricle dysfunction has been shown
to be correlated with mortality following myocardial in-
farction in the clinic [15]. These data, together with
pharmacokinetic allometric scaling to human, were used
to estimate the expected active dose in humans allowing
with the toxicological findings to design a dose escala-
ting Phase I trial to investigate the safety, tolerability
and pharmacokinetics of a single intravenous dose of
TRO40303 in preparation for a Phase II clinical trial.
Methods
Reagents
All reagents were purchased from Sigma-Aldrich (St.
Louis, MO) unless specified. TRO40303 [11] was synthe-
sized by Synkem (Dijon, France). For ex vivo experiments,
TRO40303 was dissolved in a solution of 30% HPBCD in
phosphate buffered saline at 0.5 mg/mL (± 10%). In pre-
clinical in vivo studies, TRO40303 was prepared as an
emulsion in IL30, at ~6 mg/mL. Aqueous stock solutions
of the nitrone 5,5-dimethyl-1-pyrroline N-oxide (DMPO)
were purified and checked for diamagnetism as previously
described [16]. For the clinical study, TRO40303 was
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administered as a 20 mg/mL solution in liposomes
(Northern Lipids Inc, Burnaby, Canada).
Animals
All animal procedures used were in strict accordance
with the Directive 2010/63/EU of the European Parlia-
ment. Trophos, CNRS/Aix-Marseille University and
INSERM/Institut Mondor de Recherche Biomédicale,
had valid licences for animal experimentation (agree-
ments B13-055-15, C13-055-06, C94-028-245) delivered
by the French Government. Male Wistar rats (Janvier,
Le Genest Saint Isle, France, 250280 g) were used for
in vivo myocardial infarction models. Male Sprague
Dawley rats (SD, Harlan and CERJ, France, 250300 g)
were used for the ex vivo isolated heart and pharmacoki-
netic studies. Animals were maintained in the local ani-
mal house under conventional conditions, in a room
with controlled temperature (2125°C) and a reverse
12 h light/dark cycle with food and water available ad
libitum.
Human subjects
Men and post-menopausal or hysterectomized women
aged from 18 to 70 years were eligible to participate in
the Phase I trial with the following inclusion criteria:
body mass index within 18-29 kg/m2 (inclusive), healthy
as assessed by physical examination, medical history,
vital signs, electrocardiography and all other clinical
evaluations performed at screening and admission. All
subjects gave written informed consent before any
study-related procedures. The study was conducted at a
single centre (Optimed Lyon, Lyon, France) after ap-
proval by the French Regulatory Agency AFSSAPS
and the Ethics Committee (Comité de Protection des
Personnes IV Lyon, France). The study was carried out in
accordance with the Declaration of Helsinki (1964) as
modified in Seoul (2008), the recommendations on
Good Clinical Practice (ICH E6) and the applicable
French regulatory requirement. The trial was registered
with the EudraCT number: 2010-021453-39. All the data
were collected and analysed at Optimed Lyon apart from
the pharmacokinetic analysis.
Myocardial infarction model
In all groups of rats, the left anterior descending coron-
ary artery was occluded during 35 min and released for
reperfusion as previously described [17]. For the dose
range testing, the vehicle (IL30) or TRO40303 solution
in IL30 (stock solution diluted in IL30 to administer
~1.5 mL/kg in each group) at increasing doses (0.3, 1, 3
and 10 mg/kg) were administered as a 5 min infusion
through the jugular vein starting 10 min before coronary
artery reperfusion (CAR). To evaluate the therapeutic
window, the vehicle or TRO40303 at 1 mg/kg were also
administered either 10 min before coronary artery occlu-
sion (CAO) or 10 min after CAR. Infarct size was deter-
mined by triphenyltetrazolium chloride (TTC) staining
and was calculated as a percentage of the area at risk
(AAR), 24 h after reperfusion. For the dose range experi-
ment, infarct size was expressed for all doses as a per-
cent of the vehicle group infarct size.
Pharmacokinetics and TRO40303 heart level
measurement in rats
TRO40303 was administered by intravenous (i.v.) bolus to
healthy rats at doses of 0.3, 1, 3 and 10 mg/kg in IL30
under isoflurane gas anaesthesia. A maximum of 0.25 mL
of blood was collected into lithium heparin tubes at 5, 15
and 30 min, 1 h, 2 h, 4 h, 8 h and 24 h after drug adminis-
tration (3 rats per time point). The blood samples were
cooled on ice and plasma samples were prepared within
60 min of sampling by centrifugation at 1500 g at 4˚C for
10 min and stored at 20°C until analysis. For heart level
measurements, TRO40303 was administrated i.v. to rats
undergoing the myocardial infarction procedure at the
dose of 1 mg/kg in IL30 either 10 min before CAO or
10 min before CAR. Five min after CAR, rats were anes-
thetised and sacrificed, hearts were isolated and washed
with saline. Tissue from AAR was separated from the re-
mainder of the left ventricle; samples were frozen and
stored at 20°C until analysis. After TRO40303 plasma
concentration analysis, TRO40303 plasma AUC(0-∞) (the
area under the curve extrapolated from time zero to time
infinity), was calculated using Kinetica™, version 4.4.1
(Thermo Electron Corporation, Philadelphia, PA 19103,
USA). The results were analyzed in comparison with pre-
vious pharmacokinetic data obtained with TRO40303 for-
mulated in HPBCD at 2.5 mg/kg [11].
Perfusion conditions in isolated heart model and
hemodynamic measurements
Ischemic reperfusion of Langendorff isolated rat heart
was performed as previously described [18]. Rat hearts
were perfused either with TRO40303 1 μM (0.5 mg/mL
stock in 30% HPBCD diluted 1000X in Krebs-Henseleit
(KH) buffer (n = 29)) or vehicle (30% HPBCD diluted
1000X in KH buffer (n = 24)) during 30 min equilibra-
tion, 10 min low flow ischemia, and 60 min reperfusion
following 30 min of total ischemia. During the reperfu-
sion period, the following parameters were monitored
via a water-filled latex balloon inserted into the left ven-
tricle: left ventricular end diastolic pressure (LVEDP);
left ventricular developed pressure (Pdev); its first de-
rivative (dP/dt) and heart rate. Coronary flow was mea-
sured by collecting the coronary perfusate over 1 min.
The rate-pressure product (RPP) was calculated as the
product of Pdev and heart rate. Some of the hearts from
this main experiment were used to assess ascorbate,
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reactive oxygen species (ROS) and lipid peroxidation as
described below.
Free radical and lipid peroxidation measurements
To evaluate the effect of 1 μM TRO40303 on ischemia-
reperfusion-induced ascorbate release and tissue deple-
tion, effluents from control and treated hearts undergo-
ing the perfusion protocol described above (n = 6/group)
were collected for 15 s, 1 min following onset of reflow,
and hearts were frozen in liquid nitrogen at the end of
the reperfusion period. Ascorbate content in effluents
and tissue homogenates was then assessed by quantify-
ing the ascorbyl free radical (AFR)-dimethyl sulfoxide
(DMSO) electron spin resonance (ESR) doublet as previ-
ously described [19], DMSO being used to stabilize the
ascorbate free radical.
To investigate whether TRO40303 could interfere with
ischemia-reperfusion-triggered ROS production, hearts
(n = 6) undergoing the perfusion protocol described above
received the spin trap nitrone DMPO (25 mM) during the
first 5 min of reperfusion. A 15-s collection of the effluents
was performed pre-ischemically on three additional hearts
from both groups, and 3 min after onset of reflow for the
6 ischemic/reperfused hearts. Samples were immediately
stored in liquid nitrogen. The free radical content of
DMPO-supplemented from TRO40303-treated and con-
trol effluents was determined by ESR in glass capillaries.
The ESR signal was acquired 1.5 min after thawing of the
sample using the same parameters as for ascorbate [19]
except: modulation amplitude 0.0313 mT, receiver gain 5
× 104 and sweep rate for each scan 0.167 mT/s.
Lipid peroxidation in heart tissue at the end of reper-
fusion was evaluated using the malondialdehyde-
thiobarbituric acid assay (MDA-TBA) (n = 8/group) as
previously described [18].
Complement reactogenicity in normal human sera
Reactogenicity of the liposomal formulation of TRO40303
at a final concentration of 5.5 mg/mL was assayed in vitro
for complement activation ability. SC5b-9 levels were
measured by a commercial enzyme-linked immunosorb-
ent assay (ELISA, Quidel Corporation; SC5b-9 Plus EIA
kit, Ref. A029), following the instructions of the provider,
on individual serum samples obtained from 10 healthy
volunteers at Seroscience, Hungary. Blood withdrawal and
experimentation have been carried out under conditions
approved by the regional research ethics committee
(Regional and Institutional Committee of Science and
Research Ethics, Semmelweis University. Registration
number: TUKEB 142/2008). AmBisome®, a liposome-
containing antifungal drug, amphotericin B, was used at
4 mg/mL for final lipid concentration as a positive control.
Data were compared to basal levels with no product added
to the sera.
Porcine liposome-induced cardio-pulmonary distress
model
Domestic Yorkshire pigs (12-14 weeks, ~25 kg) received
multiple i.v. injections of the test material via the external
jugular vein at 10 mL/min as follows: saline as a negative
control, the liposomal formulation of TRO40303 at
10 mg/kg and a bolus of Doxil® at 0.01 mg/kg as a positive
control. Doxil® is a marketed liposomal formulation of
doxorubicin administered intravenously that can provoke
acute infusion-related reactions [20].
Hemodynamic changes were monitored continuously
for at least 30 min after the end of each test material in-
fusion. Systemic arterial blood pressure (SAP) and pul-
monary arterial blood pressure (PAP) changes were
evaluated.
Pharmacokinetic based allometry
Pharmacokinetic based allometry (natural logarithm (ln)
transformation) was performed using available pharmacoki-
netic data (not shown) from various animal species and
was used to estimate clearance (CL) and the initial volume
of distribution (V1 =Dose/C0; C0 defined as the extrapo-
lated plasma concentration at time zero) in human. Ani-
mals had received a single i.v. bolus dose of TRO40303
administered under lipid-based formulations (Intralipid®
and liposomes) in rats and pigs or under cremophor
EL®/ethanol/saline formulation in dogs and monkeys. The
pharmacokinetic parameters were assessed from the mean
(for rodents) or individual TRO40303 plasma concentra-
tion versus time profiles using a non-compartmental ap-
proach Log Linear Method (Kinetica™, version 4.4.1). The
ln of the CL and the ln of V1 were each plotted against the
ln of the animals body weight. Finally, using this relation-
ship, the human CL and V1 were estimated based on the
human body weight ranging from 50 to 115 kg.
Clinical trial design
A randomized, double-blind, placebo controlled study
was performed to investigate the safety, tolerability
and pharmacokinetics of single i.v. ascending doses of
TRO40303 in healthy male and post-menopausal female
subjects. The choice of the dose and flow rate escalation
process is explained in the Result section. Seventy-two
healthy volunteers were randomized, with 18 receiving a
placebo and 54 an active liposomal formulation contain-
ing 20 mg/mL TRO40303 at final doses ranging from
0.5, 1, 2, 3.5, 6, 10 to 13 mg/kg with escalating flow rates
from 0.04 mL/min to 35 mL/min. Within each group, 3
or 6 subjects received TRO40303 and 1 or 2 subjects re-
ceived the same volume of placebo. The sample size was
based on the number of doses and flow rates to be in-
vestigated. The 6 verum/2 placebo ratio per group is
widely used in single ascending dose studies and pro-
vides adequate safety and pharmacokinetic information.
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The 3 verum/1 placebo ratio used in the last groups was
chosen only to explore additional flow rates at previously
studied doses.
The study started on the 14th of September 2010 and
was completed on the 24th of February 2011. The demo-
graphic characteristics of the recruited subjects are pre-
sented in Additional file 1: Table S1. The randomization
list was produced by a statistician from Optimed Lyon
and established by dose and flow rate. Subjects were
assigned a chronological treatment number from 001 to
072. All participants from Trophos and Optimed Lyon
as well as subjects were blinded to the study, except
from the pharmacist at Optimed Lyon. The blinding was
achieved by using aluminum paper to cover the content
of the syringes and tubes. Additionally, the analysis of
TRO40303 plasma level at Bertin Pharma was performed
un-blinded.
For each dose group, a decision to proceed to the next
higher dose was made based on blind safety/tolerability
data on at least 75% of the subjects up to at least 48 h
post-dose. Pharmacokinetic data up to 24 h was available
at the time of decision.
Sampling scheme and Pharmacokinetic parameters
Venous blood samples (5 mL) were collected for deter-
mination of TRO40303 concentrations in plasma at pre-
dose, end of infusion, then 5 min, 15 min, 30 min, 1 h,
2 h, 4 h, 8 h, 12 h, 16 h, 24 h, 48 h, 72 h and 96 h post
end of infusion into heparinlithium Vacutainer tubes.
The blood samples were gently inverted then centrifuged
in a refrigerated centrifuge (+4°C) within 30 min after
sampling at 1500 g for ca 10 min. The resulting plasma
was frozen in two separate labelled polypropylene tubes
at 20 ± 5°C until assaying.
After TRO40303 plasma concentration analysis, the follow-
ing parameters were calculated for each subject: TRO40303
maximum plasma concentration (Cmax), TRO40303 plas-
ma concentration at 5 min post end of infusion (C5min),
AUC(0-∞), plasma elimination half life (thalf), CL and vol-
ume of distribution (Vz), using Kinetica™, version 4.4.1 at
Trophos.
Quantification of TRO40303 in plasma and heart samples
by HPLC-MS/MS
Thawed preclinical samples were extracted with aceto-
nitrile, centrifuged, purified on SPEC C2 cartridge (Varian)
for the heart samples and analysed along with calibration
standards. Analysis was carried out on an Alliance 2695
(Waters) system interfaced to an API Quattro Micro
(Waters) MS detector. Calculations were carried out with
Waters QuanLynx software.
For the quantifying TRO40303 levels in human plasma
samples, the same method, GLP validated, was used and
the analysis was performed at Bertin Pharma (Orleans,
France). Analysis was carried out on 1200 Series (Agi-
lent) and Series 200 (Perkin Elmer) systems interfaced
to an API 4000 (AB Sciex) MS detector. Calculations
were carried out with Analyst 1.4.1 and 1.5.1 (AB Sciex)
software.
Safety and tolerability
Continuous recording of adverse events, continuous
blood pressure monitoring for 2 hours after dosing and
12-lead electrocardiogram (ECG) at pre-dose, 15 min,
1 h, 4 h, 8 h, 24 h, 72 h and 96 h after end of infusion
were performed. Vital signs, physical examination,
haematology, blood biochemistry, urinalysis and haemo-
stasis were performed before the study, at specific times
after dosing and at the end of study visit, 7 days after
administration. Blood biochemistry analysis included
ASAT, ALAT, alkaline phosphatase, triglycerides, total
cholesterol, HDL-cholesterol and LDL-cholesterol.
To assess any risk of complement activation related
pseudo-allergy (CARPA) reaction in the clinical study,
SC5b-9 levels were measured by a commercial enzyme-
linked immunosorbent assay (ELISA, Quidel Corpor-
ation; SC5b-9 Plus EIA kit, Ref. A029), following the in-
structions of the provider at Seroscience, Hungary.
Serum samples for SC5b-9 analysis were collected as de-
scribed for TRO40303 PK analysis before dosing, and
then 5, 15 and 60 min after end of infusion.
Statistical data analysis
The preclinical data are reported as mean ± S.E.M. Stat-
istical significance was determined using either two-
sided Students t-test or one-way analysis of variance
(ANOVA) followed by Dunnetts post test. Significance
was accepted when p < 0.05. The exact p value is given
when 0.01 < p < 0.05.
For the clinical data, descriptive statistics were used.
All randomized subjects were included in the analysis.
Results
Dose-effect relationship of TRO40303 in an in vivo rat model
Using the IL30 formulation, doses ranging from 0.3 to
10 mg/kg were investigated in a model of myocardial in-
farction in rats. TRO40303 or IL30 vehicle alone were ad-
ministered by i.v. bolus in a constant volume 10 min
before reperfusion following a 35 min CAO. Whereas in-
farct size determined 24 h after reperfusion was smaller
but not significantly different at the lowest tested dose of
0.3 mg/kg, 1 mg/kg significantly reduced infarct size by
40% (p < 0.01) as compared to vehicletreatment. The ef-
fect of TRO40303 reached a plateau of ~50% reduction of
infarct size compared to control (p < 0.001) with doses of
3 and 10 mg/kg (Figure 1A and Table 1).
For pharmacokinetic studies in healthy rats, TRO40303
was administered formulated in IL30 at the doses used in
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the myocardial infarction model and results analyzed in
comparison with pharmacokinetic data obtained with
TRO40303 formulated in HPBCD at 2.5 mg/kg. When
TRO40303 was formulated in IL30, exposure was higher
than previously found with TRO40303 formulated in
HPBCD. The dose of 1 mg/kg TRO40303 in IL30 pro-
vided a similar exposure as that obtained with 2.5 mg/kg
in HPBCD (Figure 1B). This correlated well with the level
of activity found with both doses in the two formulations.
The TRO40303 plasma exposure in rats in terms of
C5min and AUC(0-∞) together with the corresponding
activity in term of infarct size reduction for each dose,
were used to establish a PK/PD relationship.
The plateau of activity corresponding to ~50% infarct
size reduction was determined as the maximum achiev-
able cardioprotective activity for TRO40303 in this
model and doses achieving this level of infarct size re-
duction thus corresponded to the target plasma expos-
ure to achieve. The pharmacokinetic parameters for the
fully active doses of 3 and 10 mg/kg in rats, measured in
satellite animals similarly infused, were: C5min, 57.9 and
130 μM (23.5 and 52.8 μg/mL) and AUC(0-∞) of 14.0 and
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Figure 1 Dose effect and therapeutic window of TRO40303 in a myocardial infarction model in rats. Infarct sizes (IS) were quantified after
24 h coronary artery reperfusion (CAR) following 35 min of coronary artery occlusion (CAO), and calculated for each group as percentage of the
area at risk (AAR) and then expressed as a percentage of the IS of the control group for each dose. N is the number of treated rats per group;
circles are individual values while the mean ± S.E.M is indicated by black bars for each group; **: p < 0.01 and ***: p < 0.001 versus control.
A) TRO40303 formulated in IL30 was administrated by i.v. bolus to rats 10 min before CAR. The doses of 1, 3 and 10 mg/kg provided significant
protection in this ischemia-reperfusion model while 0.3 mg/kg did not have a significant effect using ANOVA followed by Dunnett’s post test.
The average IS of the control group (vehicle 100%) corresponded to 43.62 ± 0.04% of the AAR. B) Plasma level of TRO40303 expressed in μg/mL
during 24 h after i.v. bolus to satellite rats corresponding to the four doses tested in the IL30 formulation and compared to a pharmacokinetic
profile of the 2.5 mg/kg dose in HPBCD previously shown as active. C) One mg/kg TRO40303 formulated in IL30 reduced infarct size significantly
when administrated by i.v. bolus to rats 10 min before CAO, but not 10 min after CAR as evaluated by Student T-Test. D) Heart level of TRO40303
at 5 min after reperfusion in ischemic (AAR) or remainder of left ventricle (LV) after administration of 1 mg/kg TRO40303 formulated in IL30.
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44.8 μg.h/mL, respectively. The exposure corresponding
to the dose of 3 mg/kg was defined as the minimum
fully effective plasma exposure.
Therapeutic window of TRO40303
The therapeutic window for TRO40303 treatment was
investigated in rats by administering the lowest active
dose of 1 mg/kg in IL30 either 10 min prior to 35 min
CAO or 10 min after the onset of CAR. The results
showed that when administered before CAO 1 mg/kg
TRO40303 reduced infarct size by 55% compared to ve-
hicle (versus 40% when administered 10 min prior to
reperfusion), whereas infarct size was unchanged com-
pared to vehicletreated rats when TRO40303 was admin-
istered 10 min after the onset of reperfusion (Figure 1C).
However, in this case it must be noted that the extent
of the infarct was lower in the vehicle group when
treated 10 min after CAR compared to administration
before CAO (Figure 1C). Nevertheless, TRO40303
provided no greater effect when administered 10 min
post reperfusion. Thus TRO40303 should be adminis-
tered before the beginning of reperfusion in order to
provide cardioprotection.
The concentration of TRO40303 in heart tissue was
measured both in the ischemic AAR and in the remain-
der of the left ventricle. These data showed that when
given prior to ischemia, TRO40303 remains in the heart
during the ischemic period and is detectable at a similar
level 5 min post reperfusion as that found when the
compound was administered 10 min prior to reperfusion
(~1 μg/g; Figure 1D), which shows that TRO40303 is
rapidly accumulated into myocardial tissue and remains
stable for at least 1 h.
Functional recovery and reduction of oxidative stress by
TRO40303
In order to assess if the reduction of infarct size by
TRO40303 treatment in the in vivo myocardial in-
farction model translates into meaningful functional
recovery of the heart, an ex vivo model of ischemia-
reperfusion using the Langendorff isolated rat heart was
used to measure heart function by monitoring the
pressure of the left ventricle during ischemia and
reperfusion.
As seen by the monitoring of LVEDP (Figure 2A), the
contracture induced by the ischemic period was attenu-
ated at the time of reperfusion. The extent of the recov-
ery was greatly and significantly improved in hearts
exposed to 1 μM TRO40303. This was accompanied by
better recovery of coronary flow (Figure 2B), thus allow-
ing an improved Pdev (Figure 2C) and contractility (dP/
dt, Figure 2D). The improvement of global mechanical
performance in TRO40303treated hearts was evaluated
at reperfusion by calculating the RPP, which was signifi-
cantly higher (Figure 2E).
It has been shown that at least part of TRO40303s
mechanism of action, that correlated with cardiomyocyte
protection in vitro, involves a reduction in oxidative
stress and ROS production [11]. We used the isolated
heart model to investigate if the same mode of protec-
tion could be observed in the full organ. To address this
question, in a first set of experiments, the levels of AFR-
DMSO, which relates to ascorbate free radical content
[19] were measured by ESR spectrometry in post-
ischemic coronary effluents and myocardial tissue in
control and TRO40303treated isolated hearts. It was
previously reported that an early post-ischemic effluent
release concomitant to a decrease in tissue AFR-DMSO
was detected in untreated rat hearts during the reperfu-
sion phase [19]. Supplementing the perfusion medium
with 1 μM TRO40303 significantly inhibited AFR-
DMSO release in the coronary effluents during early
reperfusion (57% versus untreated hearts, p < 0.001
(n = 6); Figure 2F) and prevented tissue AFR-DMSO
depletion at the end of reflow (+24% versus untreated
hearts, p < 0.05 (n = 6); Figure 2G).
In a second set of experiments, the effect of infusing
TRO40303 on spin adduct formation in hearts reperfused
in the presence of the nitrone DMPO was investigated. In
both groups of hearts when the spin trap (25 mM) was
added to KH medium during the last minute preceding is-
chemia, no ESR signal was detected in effluent samples
showing that ROS production was below the level of de-
tection during normoxia (Figure 2H). DMPO and other
structural analogues have been shown to inhibit post-
ischemic spin adduct formation by protecting the heart
during ischemia [21,22]. In order to minimize this poten-
tial cardioprotection by DMPO, two additional groups of
vehicle and TRO40303treated hearts received the spin
Table 1 Effects of TRO40303 on infarct size after cardiac ischemia reperfusion in rats
Dose
(mg/kg)
AAR (% LV) IS (% LV) IS (% AAR) IS (% Vehicle IS)
TRO40303 Vehicle TRO40303 Vehicle TRO40303 Vehicle TRO40303 Vehicle
0.3 45 ± 5
54 ± 4
11 ± 2
18 ± 3
26 ± 4
33 ± 4
77 ± 15
100 ± 131 39 ± 4 7 ± 1 19 ± 2 56 ± 6
3 43 ± 4 6 ± 1 15 ± 2 44 ± 7
10 30 ± 2 35 ± 3 7 ± 2 20 ± 3 25 ± 6 56 ± 6 45 ± 10 100 ± 10
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trap (25 mM) only at reperfusion and the spin adduct con-
tent of coronary effluents was determined 3 min after the
onset of reflow, a time when maximal spin adduct produc-
tion has been reported [16,23]. In both groups of hearts a
1:2:2:1 ESR quartet characteristic of DMPO-OH, the hy-
droxyl radical (HO) DMPO adduct, was detected; how-
ever, the intensity of this signal was decreased by 69% in
the TRO40303treated group (p < 0.05 (n = 6); Figure
2H and I).
In a third set of experiments, MDA-TBA was used as an
index of myocardial lipid peroxidation. Figure 2J shows
that pre-treatment of hearts with 1 μM TRO40303 signifi-
cantly limited MDA-TBA formation as compared to
vehicle-perfused hearts (65%, p < 0.01 (n = 8)).
Dose selection for Phase I trial
The doses used in the Phase I trial were based on 1) the
starting dose calculated with the toxicology findings and
2) the predicted active dose in human that was calculated
based on two points: the target TRO40303 plasma expos-
ure (C5min, AUC(0-∞)) that correlated with the minimum
fully effective dose resulting in 50% reduction of infarct
size in rats; and the predicted pharmacokinetic parameters
in human that were calculated by allometric scaling.
The starting dose of 0.5 mg/kg was calculated from
FDA guidelines [24] based on findings from non-clinical
toxicology studies (not shown).
The CL, V1 and body weights of various preclinical
species exposed to TRO40303 were used to extrapolate
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Figure 2 Functional recovery and reduction of oxidative stress by TRO40303 in isolated rat hearts following ischemia-reperfusion.
Isolated rat hearts were perfused using the Langendorff system by solutions of KH buffer containing 0.03% HPBCD with or without TRO40303
1 μM. A: left ventricular end diastolic pressure (LVEDP), B: coronary flow, C: developed pressure (Pdev), D: contractility (dP/dt) and E: rate pressure
product (RPP) was evaluated in isolated rat hearts during 60 min of reperfusion following 30 min of no flow ischemia. A to E: Comparisons
among groups were performed using a two-way ANOVA, ***: p < 0.001 vs 0.03% HPBCD. A significant improvement in functional recovery was
observed for all the parameters when hearts were perfused with KH buffer containing TRO40303. Relative ascorbate levels were measured
through ESR detection of dimethyl sulfoxide (DMSO)-stabilized ascorbyl free radical (AFR) in the effluents (F) at the 1st min of reperfusion and in
the heart tissue (G) at the end of reperfusion. TRO40303 reduced the level of ascorbate release in the effluents while maintaining a higher level
in heart tissue. DMPO-OH release was evaluated in the coronary effluents from hearts reperfused in the presence of 25 mM DMPO: typical spectra
(H) recorded 3 min following onset of reflow for vehicle and TRO40303-treated samples; no signal was observed when hearts were perfused with
25 mM DMPO during normoxia; and determination of relative DMPO-OH levels (I) showing that TRO40303 1 μM reduced post-ischemic ROS
release. Lipid peroxidation, evaluated by MDA-TBA in the heart ventricle at the end of reperfusion, was reduced in the hearts treated by
TRO40303 compared to vehicle (J). F to J: Bars indicate mean ± S.E.M. and comparisons among groups were performed using a t-test *: p < 0.05,
**: p < 0.01 vs 0.03% HPBCD (n = 6/group).
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and predict human CL or V1 based on the relationship be-
tween the ln of these parameters with the inclusion of a 95%
confidence interval (CI) (Figure 3A and B). From this allo-
metric scaling, the predicted human CL and V1 estimated
for body weights ranging from 50-115 kg (as expected in a
future Phase II clinical trial), were 53-238 mL/h/kg and
89-741 mL/kg, respectively.
The active dose predicted for humans in this weight
range was then calculated using the formulas, Dose = CL
× AUC(0-∞) or Dose = V1 × C0, considering that C5min
value was close to C0 value. Including a 95% CI, a human
dose predicted to provide ~50% reduction in infarct size
should be between 0.7 and 3.3 mg/kg based on CL or be-
tween 2.1 and 17 mg/kg based on V1. Therefore, the Phase
I study was designed to cover doses ranging from
0.7-17 mg/kg.
Clinical TRO40303 formulation development
In order to be able to deliver an effective dose in a vol-
ume that can be administered in no more than a few
minutes, a clinical formulation was needed that provi-
ded increased drug load over that of IL30. Because
TRO40303 is highly hydrophobic but liposoluble, a clin-
ical formulation in liposomes was developed having a
concentration of ~20 mg/mL. However, liposomal prep-
arations can induce hypersensitivity reactions [25,26]
due to CARPA, which is related to the type of liposomes
and the speed of injection [27]. To avoid this side effect,
a TRO40303 liposomal formulation was developed and
selected based on the failure to stimulate production of
complement fragment, SC5b-9 in human sera. To this
end, candidate liposomal formulations of TRO40303
were assayed in vitro and selected based on the failure
to induce formation of SC5b -9 in a battery of human
sera. The positive control in these studies was AmBi-
some®, a product that is known to induce CARPA reac-
tions [28], which induced a large release (Figure 4A).
The selected formulation was then evaluated in an
in vivo model of liposome-induced cardio-pulmonary
distress in pigs, the most sensitive species for CARPA
reactions [29]. Measuring PAP in this model has been
shown to be a good indicator for human hypersensitivity
to liposomal drugs [27]. I.v. bolus administration of lipo-
somal TRO40303 at 10 mg/kg did not induce a signifi-
cant change in PAP whereas Doxil®, a product with
known susceptibility to induce infusion-related reactions
[20], greatly increased it (Figure 4B). SAP was not chan-
ged either by TRO40303 or Doxil®.
Design and results of the Phase I trial
As the Phase I trial design was focused on evaluating the
safety as well as PK parameters of TRO40303 adminis-
tered intravenously, the level of SC5b-9 was carefully
monitored and both the dose and infusion flow rate
were escalated slowly as illustrated in Figure 5. The ad-
ministration was initiated at a flow rate of 0.04 mL/min
and aimed at achieving the intended flow rate of
10 mL/min. By the time the dose of 13 mg/kg at a flow
rate of 10 mL/min was achieved, exposure levels were
already higher than predicted so the trial protocol was
amended to repeat lower doses but further increase the
flow rates to 35 mL/min.
In this study, all the tested doses and flow rates were
well tolerated clinically. There were no serious adverse
events reported. During the overall study period, 14/72
(19.4%) subjects reported the occurrence of 14 adverse
events. Four of these occurred before product adminis-
tration (3 episodes of headache and one episode of cath-
eter site pain) and 10 occurred after initiating product
administration (emergent). Among emergent adverse
events, 4 were experienced after administration of pla-
cebo. The list of the adverse events, their intensity and
their relationship to the study product is presented in
Table 2.
Figure 3 Allometry scaling to human. Clearance CL (A) and the initial volume of distribution V1 (B) were plotted against the body weight (BW)
of the animals (expressed in ln) allowing the estimation of the human CL and V1 based on the human BW as described in materiel and
method section.
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No relevant changes in vital signs, ECG parameters, la-
boratory tests or physical examinations were observed at
any time in any dose group. Nearly all measurements
were within the laboratory range or assessed as normal
by clinical assessment. The out-of-reference range values
for biochemical, hematological, vital signs and ECG pa-
rameters were judged by the investigators of no clinical
significance and no clinically relevant changes were
observed.
The evaluation of complement activation showed a
slight biological activation for 4 subjects (one in the
13 mg/kg-10 mL/min group, one in the placebo group
and two in the 10 mg/kg-35 mL/min group), none were
judged clinically significant (Figure 6). This confirmed
Figure 4 Absence of CARPA reactions using the liposomal TRO40303 formulation. A) Serum from 10 healthy volunteers were incubated
with either TRO40303 liposomal formulation at 5.5 mg/mL or AmBisome® at 4 mg/mL. After 45 min at 37°C, detection of SC5b-9 was performed
by ELISA and the mean values were compared with basal level of the sera with no compound addition. The TRO40303 liposomal formulation did
not induce SC5b -9 release whereas AmBisome® induce a significant release (***: p < 0.001 versus control). B) Systemic Arterial blood Pressure
(SAP) and Pulmonary Arterial blood Pressure (PAP) changes were evaluated in a male pig after i.v. injection of the same volume of either saline
or 10 mg/kg TRO40303 liposomal formulation infusion at 10 mg/mL followed by a bolus of Doxil® at 0.1 mg/kg. Doxil® induced an increase in
PAP whereas TRO40303 had no effect. The data presented here are typical of 5 independent experiments.
Groups A to G:
1- Dose escalation: In each group N=8  (TRO40303 N=6 or placebo N=2) 
2- Flow rate escalation: In each sub-group N=4  (TRO40303 N=3 or placebo N=1)
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Figure 5 Design of the Phase I clinical trial. Sequential dose and flow rate escalation is presented per group of subjects in the Phase I trial. For
the dose escalation, in each group A to G, consisting of eight subjects, six received TRO40303 and two the placebo; flow rate escalation was
performed in sub-groups of four subjects. In groups H to K consisting of four subjects, three subjects received TRO40303 and one the placebo.
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the safety of the TRO40303 liposomal formulation se-
lected based on the failure to stimulate production of
complement fragment SC5b-9.
TRO40303 pharmacokinetics in terms of Cmax and
AUC(0-∞) were linear from 0.5 to 6 mg/kg and slightly
~1.5-fold hyper-proportional from 6 to 13 mg/kg
(Figure 7 and Table 3). At 13 mg/kg, the mean Cmax was
259 μg/mL and the mean AUC(0-∞) was 651 μg.h/mL.
The mean penultimate thalf (when at least 80% of drug
was eliminated) was 4 h, mean terminal thalf was 25 h
and Vz was 1.1 L/kg with a moderate inter-individual
variability. Compared to the pharmacokinetic parameters
in rats, C5min is ~2-fold higher and AUC(0-∞) is ~7-fold
higher in humans for the same dose. These differences
are probably in part due to the use of different formula-
tions in the two species: IL30 in rats and liposomes in
human and might also explain the difference between
predicted CL and V1 parameters versus real data in hu-
man. The pharmacokinetic parameters per dose group
and flow rate are presented in Table 3. These data were
used to estimate the expected active dose to be used in
the phase II clinical trial [30]. In order to maximize the
potential dose in human, the highest plasma exposure
leading to 50% reduction of infarct size as determined in
the rat model to (C5min = 52.8 μg/mL) was chosen as the
target. The dose of 6 mg/kg should assure that all pa-
tients receive an effective dose based on C5min which is
the most relevant parameter for a product that should
affect events occurring at the acute time of reperfusion.
Discussion
These studies describe the successful translation of a
new cardioprotective therapy, TRO40303 from preclin-
ical proof of concept to clinical evaluation of safety, tol-
erance and measurements of human pharmacokinetic
parameters. The results support the further development
of TRO40303 to treat reperfusion injury in patients
treated by PCI for an acute myocardial infarction. Pre-
clinical ischemia-reperfusion models confirmed that
TRO40303 dose-dependently preserved heart tissue and
restored heart function. These studies also provided fur-
ther evidence that TRO40303 reduces oxidative stress
triggered by reperfusion, which along with calcium over-
load, triggers mitochondrial permeabilization underlying
cardiomyocyte cell death [31].
Similar cardioprotective effects were found when
TRO40303 was administered to rats either 10 min prior to
35 min left ventricular ischemia or 10 min before reperfu-
sion but not when administered 10 min after the onset of
reperfusion. This results show that TRO40303 targets
early events, such as mitochondria permeabilization, lead-
ing to reperfusion injury but does not act on later reperfu-
sion events. In the clinical setting, this has an important
consequence: TRO40303 should be administered before
reperfusion is performed either by angioplasty or thromb-
olysis. TRO40303 could thus be effective when adminis-
tered in an emergency situation just before PCI or
prophylactically in case of scheduled PCI or coronary ar-
tery bypass graft surgery.
The safety and tolerability of TRO40303 administered
by i.v. infusion in humans was then verified in a Phase I
trial. Intravenous doses of TRO40303 from 0.5 mg/kg to
13 mg/kg were all well tolerated. Infusion flow rates up
to a maximum of 35 mL/min were tested with doses be-
tween 3.5 and 10 mg/kg and a dose of 6 mg/kg was pre-
dicted to be able to deliver a clinically effective level of
TRO40303 at the time of reperfusion. Thus, it should be
possible to deliver this dose in less than 1 min with
TRO40303 formulated in liposomes at a concentration
of 20 mg/mL, the desired objective for an emergency in-
dication such as an acute myocardial infarction. The
dose of 6 mg/kg assures that all individuals will achieve
a C5min above 52.8 μg/mL, the plasma exposure found in
rats treated with 10 mg/kg that resulted in ~50%
Table 2 List of adverse events (AEs)
Administration Description Relationship Intensity
Non emergent AEs
(before product initiation)
0.5 mg/kg; 0.04 mL/min 1 episode of headache Non applicable Moderate
0.5 mg/kg; 0.08 mL/min 1 episode of headache Non applicable Moderate
13 mg/kg; 10 mL/min 1 episode of headache Non applicable Moderate
1 episode of catheter site pain
Emergent AEs
(after product initiation)
Placebo 2 episodes of headache 1 Unlikely, 1 Possible Mild
1 episode of myoclonus Possible
1 episode of chest pain Unlikely
0.5 mg/kg; 0.08 mL/min 2 episodes of back pain Excluded 1 Moderate and 1 Mild
2 mg/kg; 0.64 mL/min 1 episode of injection site haematoma Excluded Moderate
3.5 mg/kg; 5 mL/min 1 episode of presyncope Unlikely Moderate
6 mg/kg; 7.5 mL/min 1 episode of infusion site inflammation Probable Moderate
6 mg/kg; 23 mL/min 1 episode of vision blurred Possible Moderate
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reduction in infarct size. At a lower dose it is possible
that not all the individuals will have that level of expos-
ure at the time of reperfusion based on the observed
inter-individual variability. This dose is currently being
evaluated in a Phase II clinical trial (ClinicalTrials.gov
Identifier: NCT01374321) [30]. Notably, safety, tolerance
and most importantly the lack of CARPA-type reacto-
genicity with TRO40303 formulated in liposomes, which
is of particular importance for the security of patients
being treated for an acute myocardial infarction, was
confirmed in the Phase I study.
Limitations of these studies are that TRO40303 effi-
cacy studies have only been performed in rodent models
and that the formulation used in animal models is differ-
ent from the formulation used in humans. Additionally,
human safety and pharmacokinetics was only tested in
0 20 40 60
0
100
200
300
0 20 40 60
0
100
200
300
0 20 40 60
0
100
200
300
0 20 40 60
0
100
200
300
Time (min)
SC5b-9 Percent Change 
from Baseline
by Dose and Flow rate of 
TRO40303 administration
0.5 mg/kg_0.04 mL/min
0.5 mg/kg_0.08 mL/min
1 mg/kg_0.16 mL/min
1 mg/kg_0.32 mL/min
2 mg/kg_0.64 mL/min
2 mg/kg_1.28 mL/min
0 20 40 60
0
100
200
300
0 20 40 60
0
100
200
300
3.5 mg/kg_2.5 mL/min
3.5 mg/kg_5 mL/min
3.5 mg/kg_15 mL/min
0 20 40 60
0
100
200
300
13 mg/kg_10 mL/min
10 mg/kg_10 mL/min
10 mg/kg_35 mL/min
6 mg/kg_7.5 mL/min
6 mg/kg_23 mL/min
6 mg/kg_35 mL/min
Figure 6 Sc5b-9 plasma levels in human healthy volunteers of the Phase I trial. Seventy-two healthy volunteers were administered
increasing i.v. doses of either TRO40303 or placebo as described in the materiel and method section. Plasma level of SC5b-9 was dosed in all
subjects before administration, and then 5, 15 and 60 min after end of infusion. Percent evolution from baseline is presented for each subject.
Dose and flow rate groups are indicated by colour code. Plain circles represent subjects having received TRO40303 and open circles, subjects
having received the placebo.
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54 individuals exposed to TRO40403 and only 27 with
doses of 6 mg/kg or higher. Further development of the
product in patients is thus required in order to validate
if similar safety, pharmacokinetics and efficacy is ob-
served in the target population. Of note, it must be
pointed out that several very promising therapies in pre-
clinical models for cardiac reperfusion injury have failed
in human.
Conclusions
In conclusion, TRO40303 timing of administration,
dose-dependent efficacy and functional effects were
characterised in preclinical models of cardiac ischemia-
reperfusion injury. Safety was demonstrated in humans
in a Phase I trial and the pharmacokinetic parameters in
humans were determined confirming the therapeutic po-
tential of TRO40303 and the feasibility to perform a
Phase II proof of concept trial, which is ongoing. The
outcome of the Phase II trial will determine whether
TRO40303 reduces infarct size in humans, and provide
a path to developing it as a therapy to reduce reperfu-
sion injury, cardiac remodelling and eventually mor-
bidity and mortality following acute myocardial
infarction.
A
0.5 1 2 3.5 6 10 13
0
200
400
600
800
1000
Dose (mg/kg)
TR
O
40
30
3 
AU
C 
0-
in
fin
ity
 
(µ
g.h
/m
L)
0.5 1 2 3.5 6 10 13
0
100
200
300
400
Dose (mg/kg)
TR
O
40
30
3 
C 
m
ax
 
(µ
g/m
l)
B
Figure 7 TRO40303 plasma levels in human healthy volunteers of the Phase I trial. TRO40303 plasma Cmax (A) and AUC(0-∞) (B) have been
calculated for each exposed subject of the Phase I trial. The median as well as values for the lower and upper quartiles are presented by dose
level as boxes.
Table 3 PK parameters for TRO40303 in healthy male and female subjects following single i.v. administration
Parameter (unit) Dose level (mg/kg)
0.5 (n = 6) 1 (n = 6) 2 (n = 6) 3.5 (n = 9) 6 (n = 12) 10 (n = 9) 13 (n = 6)
Cmax (μg/mL) Mean 3.32 10.3 23.1 51.7 118 194 259
Min-max 2.31-4.85 6.06-14.1 16.0-31.1 37.7-68.7 59.5-266 130-279 167-371
CV 28.5% 29.8% 25.4% 20.8% 47.3% 23.2% 29.7%
C5min (μg/mL) Mean 2.58 9.26 23.6** 50.2 112 193 248
Min-max 1.59-3.92 5.98-12.5 16.7-26.8 37.1-68.7 51.6-266 120-279 148-371
CV 32.0% 26.7% 17.7% 22.9% 52.3% 24.3% 31.6%
AUC(0-∞) (μg.h/mL) Mean 15.5* 34.5 68.6 109 229*** 408 651
Min-max 9.13-20.9 21.0-43.0 50.7-81.5 81.0-163 147-307 303-501 468-814
CV 35.0% 21.8% 17.1% 23.6% 21.8% 18.8% 21.4%
Terminal t1/2 (h) Mean 29.5 25.1 26.4 25.1 24.4 25.3 24.4
Min-max 27.0-31.5 22.9-26.8 24.3-28.7 23.1-27.7 21.2-30.0 19.3-30.2 20.1-28.6
CV 6.3% 5.6% 6.2% 7.0% 11.1% 12.8% 12.4%
CL (mL/min/kg) Mean 0.598 0.509 0.499 0.560 0.460 0.422 0.347
Min-max 0.399-0.912 0.388-0.792 0.409-0.657 0.357-0.721 0.326-0.680 0.332-0.549 0.266-0.463
CV 39.3% 28.6% 18.7% 20.9% 25.3% 20.0% 22.7%
Vz (mL/kg) Mean 1.54 1.11 1.14 1.22 0.964 0.929 0.723
Min-max 1.03-2.49 0.899-1.77 0.910-1.52 0.723-1.52 0.611-1.34 0.624-1.44 0.599-0.989
CV 43.4% 30.5% 19.7% 20.5% 23.5% 26.8% 20.0%
*n = 4; **n = 5; ***n = 11.
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Additional file
Additional file 1: Table S1. Main baseline demographic data of healthy
male and female subjects (N = 72). This table shows the demographic
data (median, min and max values) of the subjects included in the phase
I trial by dose and flow rate.
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CI: Confidence interval; CL: Clearance; DMPO: 5,5-dimethyl-1-pyrroline N-oxide;
DMSO: Dimethyl sulfoxide; ECG: Electrocardiogram; ESR: Electron spin
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